麗
01513
麗珠醫藥
28.940
-0.400-1.36%Closed16:08 04/17 HKT
OPEN/PREV CLOSE28.500/28.880
TODAY RANGE27.900-28.580
VOL1.87M
MARKET CAP24.97B
52 WEEK RANGE25.600-41.850
AVG VOL (3M)914.70K
% TURNOVER0.21%
TURNOVER52.50M
P/E (TTM)11.146
% RANGE2.35%
EPS(TTM)2.523
P/E(FORWARD)10.371
P/B1.624
BVPS17.318
DIVIDEND1.199
P/S1.876
BETA--
DIV YIELD4.26%
FREE FLOAT MKT CAP8.43B
SHARES OUTSTANDING887.91M
NEXT EARNINGS04/21-04/27
FREE FLOAT299.81M
LOT SIZE100
EX-DATE06/13/2025
News
Press Releases
Financial Reports
Profile
Reuters·04/10 10:03
Livzon wins China trial approval for JP-1366 tablet in H. pylori eradication
Reuters·04/08 08:43
Livzon Pharma board meets to review Q1 results
Reuters·03/24 13:26
Livzon reports 2025 revenue of CNY 12 billion
Reuters·03/24 13:02
Livzon Pharmaceutical Group Publishes 2025 ESG Report
Reuters·03/24 12:55
Livzon Pharma publishes 2025 annual report
Reuters·03/06 10:53
Livzon Unit Wins Vietnam Regulator Approval for Imexpharm Tender Offer
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.